Trials / Completed
CompletedNCT02555761
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,423 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alcaftadine Ophthalmic Solution 0.25% | Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice. |
Timeline
- Start date
- 2015-10-19
- Primary completion
- 2018-03-19
- Completion
- 2018-03-19
- First posted
- 2015-09-22
- Last updated
- 2019-07-05
Locations
81 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02555761. Inclusion in this directory is not an endorsement.